Medication info
Dapagliflozin and Metformin Extended-Release Tablets 10/500 mg

Dapagliflozin and Metformin Extended-Release Tablets 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Pink, double-convex, oval film-coated extended-release tablet
Packaging
30 tablets/bottle, 200 tablets/bottle, 30 tablets/box [(6 tablets/PTP*5)]
Approval status
Active

MFDS item code 202301896 · Approved 2023.06.21 · Insurance code 665003290

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received treatment for diabetes and in whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients who have not previously received treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Any change in treatment in patients with type 2 diabetes should be made with careful monitoring, as it may lead to changes in glycemic control. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted via the kidneys and renal function tends to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular disease
  • cardiovascular risk factors
  • cardiovascular events
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes when used in combination with dapagliflozin and metformin. It is administered alongside dietary and exercise therapy, and is particularly effective in patients who are not well-controlled with blood sugar levels. It may also reduce the incidence of cardiovascular events in type 2 diabetes patients with cardiovascular disease or risk factors; therefore, it should be taken according to a healthcare professional's instructions. This medication provides positive effects on blood glucose management and cardiovascular health.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received treatment for diabetes and in whom adequate glycemic control cannot be achieved with monotherapy alone: When used as initial therapy in patients who have not previously received treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Any change in treatment in patients with type 2 diabetes should be made with careful monitoring, as it may lead to changes in glycemic control. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted via the kidneys and renal function tends to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication contains metformin and dapagliflozin and is a diabetes treatment that helps in blood glucose control. It may very rarely cause a serious condition called lactic acidosis; therefore, it should not be used in patients with poor kidney function, severe infection, dehydration, or heart disease. Also, caution is needed when taken alongside other diabetes medications such as insulin or sulfonylureas due to the risk of hypoglycemia. Patients with moderate to severe kidney impairment, acute illness, or those scheduled for surgery should discontinue or use this medication carefully. Women who are pregnant or breastfeeding should not use this medication, and special caution is required for children and the elderly. During the use of this medication, side effects such as dehydration, low blood pressure, genital infections, and urinary infections may occur, so immediate consultation with healthcare personnel is necessary upon occurrence of symptoms. Additionally, vitamin B12 deficiency might occur; therefore, blood tests are recommended for long-term users. This medication should be temporarily stopped before specific tests or surgeries, and excessive alcohol consumption should be avoided during use. In case of overdose, immediate medical attention is required, and dialysis or other measures may be necessary depending on symptoms. Patients should be cautious of symptoms such as dizziness while driving or operating machinery, and keep this medication out of the reach of children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • indigestion
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • neurogenic hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect from air and moisture. It is essential to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, double-convex, oval film-coated extended-release tablet

Package unit

30 tablets/bottle, 200 tablets/bottle, 30 tablets/box [(6 tablets/PTP*5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.